Log in

NASDAQ:TNDM - Tandem Diabetes Care Stock Price, Forecast & News

$86.03
+3.01 (+3.63 %)
(As of 02/17/2020 04:08 AM ET)
Add
Today's Range
$84.50
Now: $86.03
$87.20
50-Day Range
$58.89
MA: $69.23
$86.03
52-Week Range
$47.36
Now: $86.03
$87.20
Volume1.83 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 Insulin Delivery System with Basal-IQ Technology; t:slim X2 with G5 Integration; and Tandem Device Updater that allows users to update their pump's software. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:TNDM
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees653
Next Earnings Date2/24/2020 (Confirmed)
OptionableOptionable

Receive TNDM News and Ratings via Email

Sign-up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter.


Tandem Diabetes Care (NASDAQ:TNDM) Frequently Asked Questions

What is Tandem Diabetes Care's stock symbol?

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

When did Tandem Diabetes Care's stock split? How did Tandem Diabetes Care's stock split work?

Tandem Diabetes Care's stock reverse split before market open on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.

How were Tandem Diabetes Care's earnings last quarter?

Tandem Diabetes Care Inc (NASDAQ:TNDM) issued its earnings results on Tuesday, April, 30th. The medical device company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.10. The medical device company had revenue of $66 million for the quarter, compared to the consensus estimate of $47.55 million. The business's revenue for the quarter was up 141.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.82) EPS. View Tandem Diabetes Care's Earnings History.

When is Tandem Diabetes Care's next earnings date?

Tandem Diabetes Care is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Tandem Diabetes Care.

How can I listen to Tandem Diabetes Care's earnings call?

Tandem Diabetes Care will be holding an earnings conference call on Monday, February 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for TNDM?

14 analysts have issued 12-month target prices for Tandem Diabetes Care's shares. Their forecasts range from $65.00 to $100.00. On average, they anticipate Tandem Diabetes Care's stock price to reach $79.79 in the next year. This suggests that the stock has a possible downside of 7.3%. View Analyst Price Targets for Tandem Diabetes Care.

What is the consensus analysts' recommendation for Tandem Diabetes Care?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tandem Diabetes Care.

Has Tandem Diabetes Care been receiving favorable news coverage?

News headlines about TNDM stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Tandem Diabetes Care earned a coverage optimism score of 1.8 on InfoTrie's scale. They also assigned headlines about the medical device company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Tandem Diabetes Care.

Are investors shorting Tandem Diabetes Care?

Tandem Diabetes Care saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 6,970,000 shares, an increase of 17.7% from the December 31st total of 5,920,000 shares. Based on an average trading volume of 1,460,000 shares, the days-to-cover ratio is presently 4.8 days. Currently, 12.5% of the shares of the stock are sold short. View Tandem Diabetes Care's Current Options Chain.

What other stocks do shareholders of Tandem Diabetes Care own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Ryder System (R), Pandora Media (P), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Netflix (NFLX), Tesla (TSLA) and Paypal (PYPL).

Who are Tandem Diabetes Care's key executives?

Tandem Diabetes Care's management team includes the folowing people:
  • Mr. Kim D. Blickenstaff, Exec. Chairman (Age 67)
  • Mr. John F. Sheridan, Pres & CEO (Age 64)
  • Mr. Brian B. Hansen, Exec. VP & Chief Commercial Officer (Age 51)
  • Ms. Leigh A. Vosseller, Exec. VP, CFO & Treasurer (Age 46)
  • Mr. Manuel Jaime, Sr. VP of Technology & Digital Health

Who are Tandem Diabetes Care's major shareholders?

Tandem Diabetes Care's stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (3.97%), Fred Alger Management LLC (2.43%), State Street Corp (2.26%), Delphi Management Partners VIII L.L.C. (1.69%), Eagle Asset Management Inc. (1.67%) and Goldman Sachs Group Inc. (1.27%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Richard P Valencia and Susan Morrison. View Institutional Ownership Trends for Tandem Diabetes Care.

Which major investors are selling Tandem Diabetes Care stock?

TNDM stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Lord Abbett & CO. LLC, Fred Alger Management LLC, Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Marshall Wace North America L.P., Driehaus Capital Management LLC and Columbus Circle Investors. Company insiders that have sold Tandem Diabetes Care company stock in the last year include Brian B Hansen, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Howard E Greene Jr, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller and Susan Morrison. View Insider Buying and Selling for Tandem Diabetes Care.

Which major investors are buying Tandem Diabetes Care stock?

TNDM stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Delphi Management Partners VIII L.L.C., Jennison Associates LLC, Perceptive Advisors LLC, UBS Asset Management Americas Inc., J. Goldman & Co LP, Parkman Healthcare Partners LLC and Goldman Sachs Group Inc.. Company insiders that have bought Tandem Diabetes Care stock in the last two years include Dick Allen and Richard P Valencia. View Insider Buying and Selling for Tandem Diabetes Care.

How do I buy shares of Tandem Diabetes Care?

Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Tandem Diabetes Care's stock price today?

One share of TNDM stock can currently be purchased for approximately $86.03.


MarketBeat Community Rating for Tandem Diabetes Care (NASDAQ TNDM)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  497 (Vote Outperform)
Underperform Votes:  494 (Vote Underperform)
Total Votes:  991
MarketBeat's community ratings are surveys of what our community members think about Tandem Diabetes Care and other stocks. Vote "Outperform" if you believe TNDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TNDM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Featured Article: Pattern Day Trader

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel